Journal
BREAST CANCER RESEARCH
Volume 3, Issue 3, Pages 146-149Publisher
BMC
DOI: 10.1186/bcr288
Keywords
breast cancer; inhibitors; telomerase; telomeres; therapy
Categories
Funding
- NCI NIH HHS [CN85139, CN85143] Funding Source: Medline
- DIVISION OF CANCER PREVENTION AND CONTROL [N01CN085143, N01CN085139] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Current therapies for breast cancer include treatments that are toxic and often result in drug resistance. Telomerase, a cellular reverse transcriptase that maintains the ends of chromosomes (telomeres), is activated in the vast majority of breast cancers lover 90% of breast carcinomas) but not in normal adjacent tissues. Telomerase is thus an attractive target for both diagnosis and therapy because of its distinct pattern of expression. We address the use of telomerase in the diagnostics of breast pathology, as well as the use of telomerase inhibitors in the treatment and prevention of breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available